{"id":975,"date":"2010-06-16T07:01:29","date_gmt":"2010-06-16T11:01:29","guid":{"rendered":"http:\/\/blogs.nejm.org\/?p=975"},"modified":"2015-06-04T15:25:02","modified_gmt":"2015-06-04T19:25:02","slug":"another-hiv-drug-development-programs-bows-out","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/another-hiv-drug-development-programs-bows-out\/2010\/06\/16\/","title":{"rendered":"Another HIV Drug Development Program Bows Out"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-full wp-image-978\" title=\"syzygium\" src=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/wp-content\/uploads\/sites\/2\/2010\/06\/syzygium1.jpg\" alt=\"syzygium\" width=\"212\" height=\"193\" \/>Last month, <a href=\"www.avexa.com.au\" target=\"_blank\">Avexa<\/a> announced that they will not be going forward with their development of the <a href=\"http:\/\/www.aidsmap.com\/en\/news\/C9CB26F5-748A-43F1-9B29-8475FB8F0C73.asp\" target=\"_blank\">investigational NRTI apricitabine<\/a>.<\/p>\n<p>Now <a href=\"http:\/\/www.myriad.com\/\" target=\"_blank\">Myriad<\/a> says its program to develop bevirimat <a href=\"http:\/\/www.aidsmap.com\/en\/news\/00439AAD-4420-420D-A1E0-6BDFD8EBB4AE.asp\" target=\"_blank\">is closing as well<\/a>.<\/p>\n<p>The problems with these drugs &#8212; twice daily dosing with apricitabine, formulation and mixed responses\u00a0with bevirimat &#8212; are not the real story here, since arguably we have overcome these\u00a0hurdles with investigational drugs before.<\/p>\n<p>Nope, the real issue here is that the challenge of HIV drug development\u00a0 has become staggeringly high due to the very success of our current therapies.\u00a0 Who wants to spend the resources on therapies for drug resistance when hardly anyone fails treatment anymore?<\/p>\n<p>Which leaves me wondering:\u00a0 what are we going to do with that small population of patients who have <em>literally no drug options?<\/em> The group with NRTI, NNRTI, PI, enfuvirtide, and integrase resistance who have dual-mixed tropic virus?<\/p>\n<p>Time for &#8220;orphan drug&#8221; status for investigational HIV drugs that meet this need?\u00a0 Certainly some sort a national collaborative effort would be welcome, as most practices have very few of these unfortunate patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Last month, Avexa announced that they will not be going forward with their development of the investigational NRTI apricitabine. Now Myriad says its program to develop bevirimat is closing as well. The problems with these drugs &#8212; twice daily dosing with apricitabine, formulation and mixed responses\u00a0with bevirimat &#8212; are not the real story here, since [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,4,5,8,10],"tags":[80,112,290,423,798],"class_list":["post-975","post","type-post","status-publish","format-standard","hentry","category-health-care","category-hiv","category-infectious-diseases","category-patient-care","category-research","tag-apricitabine","tag-bevirimat","tag-drug-development","tag-hiv","tag-research"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=975"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/975\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}